A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety of an experimental drug,
OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal
antibody and was developed to target cancer stem cells. Based on preclinical studies, it is
believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the
productive growth of new blood vessels, which tumors need to grow and spread.